Phone: 27162321, 27162352, 27162530, Ext. 575
Fax: 27162462, 27162956
e-mail: msiva@svce.ac.in

Academic Appointments

• Professor & Head, Department of Biotechnology,Sri Venkateswara College of Engineering
  Sripermbudur, Tamil Nadu - Teaching and Research
  
• Professor & Head, Department of Biotechnology , Head GCT, Anna University, Coimbatore, Tamil Nadu
  INDIA - Teaching and Research & Administration (2002-06)
• Director, cGMP Laboratory, Curevac/St. Vincents, New York, NY,USA - Production of recombinant
  virus vaccines and melanoma vaccines (1998-2002)
• Program Director, Surgical Research Laboratory,St. Vincent's Hospital,New York, NY USA - Teaching and Research,Laboratory Administration (1997-2002)
• Research Manager, Department of Surgery, St. Vincent's Hospital,New York NY USA - Teaching and research;Immunology & cancer vaccines (1991-1997)
• Associate Professor, Department of Surgery,NY Med. College, Valhalla USA, Immunology Research
  (1998-2002)
  
• Assist.Professor, Department of Surgery NY Med. College, Valhalla, USA, Immunology Research
  (1992-1998)
  
• Director, Surgical electives,New York Medical College Valhalla, USA, Tumor Immunology
  (1991-2002)
  
• Lecturer, Junior College, India - Chemistry (1980-82)

Education and Training:

• PhD - Madras University,Cancer Institute, Madras,India, "Radioimmunolocalization of a murine lymphoma" July 1987
• MSc - Madras University, India - Biochemistry,Fermentation Technology, July 1980
• BSc - Madras University, India - Chemistry , July 1978.
• BEd - Madurai University, India - Physical Science 1982.
• Research Associate - Mt. Sinai Medical Center,Miami Beach, FL, Immunotherapy, 1989-1991
• PDF - University of Connecticut ,Health Center, Farmington, CT , Cellular Immunology & Molecular Biology, 1987-89.
• Senior Research Fellow - Cancer Institute Madras, India, Immunology, 1985-87.
• Junior Research Fellow, Cancer Institute, Immunology, 1982-85

• Certification Course on Animal Care and Use, Columbia University, New York, 1992
• Recombinant Techniques and Application, ATCC, Rockville, MD 1994
• Certificate in Fluorescence Spectroscopy, University of Maryland, Baltimore, MD 1997
• Certificate in Information Management, 1998 New York University, New York, NY, 1998
• Certificate in Good Manufacturing Practice for Laboratories, GMP Institute, Cincinnati, OH, 1999.
• Webmaster Certification, Queens College, NY, 2000
• Certificate in QA/QC Systems, Parenteral Drug Association, Baltimore, MD 2001
  
  Industrial experience:

• Biochemist (Quality control), Chemtech Chennai,India - Manufactures blood products
  (human IgG, Albumin, antibodies),1980
• Scientific Director, Curevax LLC,Flemington, NJ, USA, Manufactures vaccines, 1996
  

Honors and Awards:

• Received research fellowships from the CSIR, DST;
• Research grants, meeting and workshop grants from BRSG, USA, National Immunotherapy Foundation,
• USA, TEQIP, New Delhi, DBT, and AICTE.
  
• Appreciation and outstanding awards by the St. Vincents Hospital/NewYork Medical College, USA and
• Best Teacher award, Government College of Technology, Coimbatore.
  
• Collaborations with investigators from institutions such as Wistar Institute, USA, Yale University, USA, Pasteur Marieux, Lyon, France, PWD, Ooty, India and with industries such as Deck-Tek, New Orleans, USA, Curevax, USA.
  
• Member in the Editorial Board of American Journal of Chinese Medicine,USA.
  
• Founding member of the Curevax Inc. USA Association for Biotechnologists, Coimbatore.
  
• Invited speaker in OBGYN Annual Meeting 1995, Germany. Invited speaker/Chief Guest in more than 25 institutions from Tamil Nadu.
  
• Member in the Board of Studies (Autonomous GCT, Anna University), Member in Academic Council (GCT, Barath Institute of Engineering and Research - Deemed University), /Member in Committees such as
• Faculty hiring Committee (PSG Tech, Kumaraguru College of Tech, KSR College, etc), Subject Expert Committee (TNAU, Barathier University, Barathidasan University); Chief Superintendent, examiner - Anna University, Barathier Univeristy, Alagappa Univeristy, Avinasilingham University.
  Who's Who in the East, 1996 Edition.
  
• Patent applied on Vaccinia virus-modified dendritic cell-based melanoma vaccine - USA.

Society & Committee membership:

• Indian Society of Immunologists - 1986
• Indian Society for Clinical Oncologists - 1987
• American Association for Cancer Research, 1990-present
• American Association for Advancement of Science, 1991-present.
• American Association of Animal Sciences, 1991-present.
• New York Academy of Science 1994-present.
• Society for Biological Therapy, 1992-present
• International Society for Vaccines, 1997-present.
• American Chemical Society, 1999-present.
• Parenteral Drug Association, 2001 - present
• Association for Biotechnologist, Coimbatore, 2002-
• Institutional animal research and use committee 1991-2002
• Institutional animal facility committee 1992-2002
• Institutional research committee 1992-1999
• Medical Faculty, St. Vincents Hospital 1992-2002
• TNAU, Coimbatore, Genetically Modified Organisms-Safety Review Committee, 2004-

List of publications:

1. Udayachander, M., Meenakshi, A., Muthiah, R and Sivanandham, M. Tumor targeting potential of liposomes conjugating Ga-67 and antibody to Dalton's lymphoma associated antigen (anti-DLAA). Int. J. Rad Oncol. Biol. Physics. 13:1713-1719, 1987.

2. Udayachander, M., Meenakshi, A and Sivanandham, M. Tumor imaging of Dalton's lymphoma using antibody Desferal-Ga-67 complex. Int. J. Rad. Oncol. Biol. Physics. 16:731-736, 1989.

3. Mukherji, B., Amala Guha, Chakraborthy, N. G., Sivanandham, M., Nishad, A., and Ergin, M.T. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med. 169(6):1961-1976, 1989.

4. Sivanandham, M and Mukherji, B. Functionally different HTLV I infected T cell lines with same phenotype derived from a patient with melanoma. Immunol. Lett. 23:149-154, 1989.

5. Mukherji, B., Chakravorthy, N.G. and Sivanandham, M. T cell clones that react against autologous tumor. Immunological Rev. 116:33-62, 1990.

6. Chakravorthy, N.G., Twardzik, D.R., Sivanandham, M Ergin, M.T., Hellstorm, K.E. and Mukherji, B. Autologous melanoma-induced activation of regulatory T cells that suppress the cytotoxic response. J. Immunol. 145: 2359-2364, 1990.

7. Sivanandham, M., Mukherji, B., Chakravorty, N. G and Robbins, J.A. Clonal expansion of T cell following in vitro stimulation of autologous melanoma cells and interleukin-2. Studied by molecular analysis of T cell receptor. Immunol. Lett. 28: 155-160, 1991.

8. Sivanandham, M., Scoggin, S. D., Sperry, R. G., and Wallack, M. K. Prospects for gene therapy and lymphokine therapy for metastatic melanoma. Ann. Plas. Surg. 28:311-314, 1992.

9. Scoggin, D. S., Sivanandham, M., Sperry, R. and Wallack, M. K. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate. Ann. Plas. Surg. 28:196-198, 1992.

10. Wallack, M. K., Scoggin, S. D. and Sivanandham, M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mount Sinai J. Med. 59:227-233, 1992.

11. Wallack, M. K. and Sivanandham, M. Clinical trials of VMO for melanoma. Ann. N Y Acad. Sci. July 1993.

12. Sivanandham, M., Scoggin, S. D., Sperry, R. G. and Wallack, M. K. Therapeutic effect of oncolysate prepared with the Interleukin-2 gene encoded vaccinia virus: study with the C-C36 murine colon hepatic metastases model. Cancer Immunol. Immunother. 38:259-264, 1994

13. Tanaka, N., Sivanandham, M. and Wallack, M.K. Active specific immunotherapy of vaccinia colon oncolysate prepared with IL-2 gene encoded vaccinia virus in combination with interferon alpha in a syngeneic murine colon adenocarcinoma. J. Immunotherapy 16:283-293, 1994

14. Sivanandham, M. and Wallack, M.K. Clinical application of viral oncolysates. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (Ed), 2nd edition, Biological Therapy of Cancer, Lippincott Company, Philadelphia, 1994

15. Sivanandham, M., Tanaka, N., and Wallack, M.K. Cytokine encoded recombinant vaccinia virus in the active specific immunotherapy of cancers. Proceedings of the XVI International Cancer Congress, p 505-509, New Delhi, India, 1994.

16. Tanaka, N. Sivanandham, M and Wallack, M.K. Role of interferon- (IFN- ) in the active specific immunotherapy of vaccinia colon oncolysate plus IFN- . Surg. Forum, XLV: 527-529, 1994

17. Sivanandham, M. and Wallack, M. K. Immunology, serum markers, and immunotherapy of mammary cancer, p 581-595 In: Donegan W L. and Spratt J. S. (Ed): Cancer of the breast. Philadelphia, W. B. Saunders company, 1995

18. Wallack, M.K., Sivanandham, M., Balch C., Urist, M., Bland, K.I., Murray, D., Daley, J.M., Robinson, W.A., Flaherty, L., Richards, J.M., Bartolucci, A.A. and Rosen, L. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate (VMO) active specific immunotherapy for patients with stage II (UICC) melanoma. Cancer, 75:34-42, 1995

19. Wallack, M.K., Sivanandham, M., Kristen, D., Whooley, B. and Bartolucci, A. Favorable clinical responses in subsets of patients from a randomized multi-institutional melanoma vaccine trial. Annals of Surgical Oncology 3(2): 110-117, 1996

20. Herlyn D, Pereira S, Maruyama H, Van Belle P, Sivanandham M, Wallack M, Elder D, and Siegel D. Identification of tumor antigens using antibody phage display. IBC Biomedical Library Series "Antibody Engineering: New Technologies, Applications and Commercialization" p90-102, 1996.

21. Pereira S, Van Belle P, Elder D, Maruyama H, Jacob L, Sivanandham M, Wallack M, Siegel D, and Herlyn D. Combinatorial antibodies against human malignant melanoma. Hybridoma 16:11-16, 1997.

22. Wallack, M.K., Sivanandham, M., Kristen, D.,Balch C., Urist, M., Bland, K.I., Murray, D., Daley, J.M., Robinson, W.A., Flaherty, L., Richards, J.M., Bartolucci, A.A. and Rosen, L. Increased Survival of Patients Treated with a Vaccinia Melanoma Oncolysate Vaccine: Second Interim Analysis of Data from a Phase III, Multi-institutional Trial. Annals of Surgery 226:198-206, 1997.

23. Shaw, P.M., Sivanandham, M., Ditaranto, K., Wallack, M.K. Adjuvant immunotherapy for patients with melanoma of the head and neck. Head and Neck:19: 595-603, 1997.

24.Sivanandham, M., Shaw P., Ditaranto, K. and Wallack, MK. Active specific immunotherapy with vaccinia melanoma oncolysates for patients with melanoma - An overview. Vaccine Research 5(4): 215-232, 1996

25. Sivanandham, M., Shaw, P.M., Bernik, S,F., Ditaranto, K., Bernstein, C., Wallack, M.K., Paoletti, E. Colon Adenocarcinoma Cells Infected with B7.1 Gene Encoding Replication Deficient Vaccinia Virus (NYVAC-B7) Induced Anti-tumor Immunity in Syngeneic Mice. Cancer Immunol Immunother 46:261-267, 1998.

26.Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richard JM, Bartolucci AA, and Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multi-center vaccinia melanoma oncolysate trial. J Am Coll Surg. 187: 69-79, 1998.

27. YuFang Yang, Sivanandham M, Nahal A, and Wallack MK. Dendritic cells pulsed with vaccinia virus augmented colon tumor cell lysate therapy increased the survival of mice bearing CC-36 colon tumor. Surgical Forum Volume XI: 256-257, 1999.

28. Sivanandham, M, Stavropoulus, CI and Wallack, MK. Whole cell and lysate vaccines. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (Ed), 3nd edition, Biological Therapy of Cancer, Lippincott Company, Philadelphia, 2000

29. Strvropoulus CI, Sivanandham M, and Wallack MK. Active specific immunotherapy for Melanoma - Commentary. In: Silberman, H (Ed) Difficult problems in surgery. Wiely Press, Philadelphia, 2000

30. Kim EM, Sivanandham M, Strvropoulus CI and Wallack MK. An overview analysis of adjuvant immunotherapy for melanoma. Journal Surgical Oncology (2001) 10: 53-59.

31. Sivanandham M, Strvropoulus CI, Kim EM, Mancke B, and Wallack MK. Flt-3 ligand gene-transduced CC-36 cells plus interleukin-2 therapy increased the survival of mice bearing syngeneic tumor. Cancer Immunology Immunotherapy (2002) 51:63-71.

32. Sivanandham M, Kim EM, and Wallack MK. Experimental Melanoma Vaccine. Idrugs. (2002) 5(2): 159-170.

33. Kim EM, Sivanandham M, and Wallack MK. Commentary - Viruses for therapeutic agents for cancer. Oncology (In Press)

34. Kim EM, Sivanandham M, Strvropoulus CI, Brain M, and Wallack MK.Flt-3 ligand gene-transduced xenogeneic cells plus interleukin-2 therapy increased the survival of mice bearing syngeneic CC-36 colon tumor. J Surg. Res. 108(1):148-56, 2002.

35. Sivanandham, M. Kim EM, and Wallack, M. K. Immunology, Serum Markers, and Immunotherapy of Mammary Cancer. p 581-595 In: Donegan W L. and Spratt J. S. (Ed): Cancer of the breast. 3rd Edition. Philadelphia, W. B. Saunders Company, 2002

36. Sivanandham M, Jayanthi S, and Vani V. Overview on Edible Vaccines. Proc. Natl. Sem. GM Crops, Pp53-57, Sep 2002, DBT-KASC, Coimbatore, India

37. Ramakrishnan V, Vani V, Jayanthi S, and Sivanandham M. Review of Genetically-Modified Medicinal Plants. Proc. Natl. Sem. GM Crops Pp58-60, Sep 2002, DBT-KASC, Coimbatore, India

38. Sivanandham M. Grant Writing, Intellectual Property Rights, and Research Ethics. p 54-60. Proc. Emerging Trends in Engineering and Science - Orientation Program for Researchers, May 19th - June 1st, 2003, Government College of Technology, Coimbatore, India

39. Sivanandham M and Vani V. Prospects of Edible Vaccines. Advanced Biotechnology II(8): 17-23, 2004

40. Sivanandham M. Intellectual Property Rights and Research Ethics. p 54-60. Proc. Emerging Trends in Engineering and Science - Orientation Program for Researchers, 2005, Government College of Technology, Coimbatore, India

41. Sivanandham M. Prospects of Dendritic Cell Vaccine, Proceedings of the International Conference on the Current Trends in Biotechnology, Barath Institute of Higher Learning, Deemed University, Chennai January 2006

In addition, more than 50 presentations in meetings and conferences.